Tominaga et al. demonstrated that RPN2 can facilitate the glycosylation of CD63, which subsequently induces multidrug resistance protein 1 (MDR1) glycosylation-mediated membrane translocation, leading to the breast cancer progression and drug resistance7,8. This evidence concerns the gene RPN2 and breast carcinoma.